Cordero, Alberto; Nuñez, Julio; Bertomeu-González, Vicente - 2022
Background: The angiotensin receptor neprilysin inhibitor sacubitril-valsartan is included in the first-line treatment for patients with heart failure (HF) and left ventricle ejection fraction (LVEF). Three clinical trials have evaluated the effect of sacubitril-valsartan in 3 different clinical...